Call your physician for advice on possible side effects. Call your doctor if you have any new or worsening symptoms. The following are typical adverse reactions to molnupiravir: If you experience any of the following symptoms of an allergic reaction to molnupiravir: hives, trouble breathing, swelling of your face, lips, tongue, or throat, seek emergency medical attention. Molnupiravir side effects (more detail) There may be additional side effects; this is not a comprehensive list. Call 1-800-FDA-1088 to report side effects to the FDA. nausea, dizziness, or gastrointestinal symptoms
Asymptomatic or pre-symptomatic Infection: People who test positive for SARS-CoV-2 by virologic testing using a molecular diagnostic (such as a polymerase chain reaction) or antigen test, but have... Asymptomatic or pre-symptomatic infection: People who test positive for SARS-CoV-2 via virologic testing using a molecular diagnostic (for example, polymerase chain reaction) or antigen test but do not exhibit any symptoms. People who have multiple organ dysfunction, septic shock, or respiratory failure are said to have a critical illness. Treatment of C0VID-19 in non-hospitalized patients with mild or moderate disease is authorized for emergency use as an oral therapeutic. Mild illness: People who exhibit any of the COVID-19 symptoms (such as fever, coughing, sore throat, malaise, headache, and muscle pain) but do not exhibit dyspnea, shortness of breath, or abnormal chest imaging. Patients with moderate illness have oxygen saturation (Sp02) levels above 94% in room air at sea level and clinical evidence of lower respiratory disease. An antiviral drug called molnupiravir is used to treat adults with mild to moderate C0VID-19 (caused by SARS-CoV-2) who are at high risk of developing severe illness. People with C0VID-19 may benefit from using molnupiravir to feel better and keep them out of the hospital. Read more Adults who are at risk of developing a severe illness can take the antiviral drug mlnupiravir to treat mild to moderate C0VID-19 (caused by SARS-CoV-2). Patients with respiratory frequency >30 breaths per minute, Sp02 94% on room air at sea level, a Pa02/Fi02 ratio 300 mmHg, or lung infiltrates >50% are considered to be suffering from a severe illness.
Serious and unexpected adverse events may occur that have not been previously reported with Molnupiravir use. For Molnupiravir, there are few clinical data available.